|
N
|
16
|
64
| |
|
Age, years
|
73 (53–78)
|
71 (51–78)
| |
|
Male / female
|
6 / 10
|
24 / 40
| |
|
Dead within one-month
|
7 (44%)
|
9 (14%)
|
p = 0.014
|
|
Diagnosis (%)
| | | |
|
Bacterial pneumonia (verified)
|
3 (19%)
|
13 (20%)
| |
|
Pneumonia, pathogen not identified
|
6 (39%)
|
31 (48%)
| |
|
Acute bronchitis
|
5 (31%)
|
12 (19%)
| |
|
Lung malignancy
|
0
|
2 (3%)
| |
|
Cardiac disease
|
1 (6%)
|
4 (6%)
| |
|
Other
|
1 (6%)
|
3 (5%)
| |
|
Concurrent diseases (%)
| | | |
|
Unknown/None
|
1 (6%)
|
32 (50%)
| |
|
COPD
|
10 (63%)
|
13 (20%)
| |
|
Malignancy
|
1 (6%)
|
4 (6%)
| |
|
Lymphoma and bone marrow-transplant
|
1 (6%)
|
1 (2%)
| |
|
NYHA III/IV
|
1 (6%)
|
13 (20%)
| |
|
NYHA III/IV and COPD
|
1 (6%)
|
1 (2%)
| |
|
Chronic renal failure
|
0
|
1 (2%)
| |
|
Renal transplantation and malignancy
|
1 (6%)
|
0
| |
|
Total number with concurrent diseases
|
15 (94%)
|
32 (50%)
|
p = 0.004
|
|
Immunosuppressive therapy (%)
| | | |
|
None
|
4 (25%)
|
56 (87%)
| |
|
Steroids alone
|
10 (63%)
|
7 (11%)
|
p < 0.001
|
|
Chemotherapy alone
|
0
|
1 (2%)
| |
|
Chemotherapy and steroids
|
1 (6%)
|
0
| |
|
Azathioprine and steroids
|
1 (6%)
|
0
| |
|
Total number receiving steroids
|
12 (75%)
|
8 (13%)
| |
|
Corticosteroid dosea
|
37,5 (8,8–58,8)
|
7.5 (5–27,5)
|
p = 0.026
|
|
Duration of corticosteroid therapy, weeks (range)
|
66 (1–102)
|
8 (1–42)
|
p < 0.001
|
